Volume 29, Number 3—March 2023
Synopsis
Multicenter Retrospective Study of Vascular Infections and Endocarditis Caused by Campylobacter spp., France
Claire Tinévez
, Philippe Lehours, Anne-Gaëlle Ranc, Yaniss Belaroussi, Fanny Velardo, Damien Dubois, Catherine Neuwirth, Hélène Pailhoriès, Marie Dorel, Genevieve Hery-Arnaud, Olivier Join-Lambert, Emmanuelle Gras, Stéphane Corvec, Cyrielle Codde, Damien Fournier, Hugo Boijout, Violaine Doat, Leslie Bouard, Anne-Sophie Lagneaux, Maxime Pichon, Célia Couzigou, Claire Letellier, Adrien Lemaignen, Emmanuelle Bille, Xavier Bérard, Caroline Caradu, Claire Webster, Didier Neau, Charles Cazanave, Mathilde Puges, and the Campylobacteremia Study Group
, Philippe Lehours, Anne-Gaëlle Ranc, Yaniss Belaroussi, Fanny Velardo, Damien Dubois, Catherine Neuwirth, Hélène Pailhoriès, Marie Dorel, Genevieve Hery-Arnaud, Olivier Join-Lambert, Emmanuelle Gras, Stéphane Corvec, Cyrielle Codde, Damien Fournier, Hugo Boijout, Violaine Doat, Leslie Bouard, Anne-Sophie Lagneaux, Maxime Pichon, Célia Couzigou, Claire Letellier, Adrien Lemaignen, Emmanuelle Bille, Xavier Bérard, Caroline Caradu, Claire Webster, Didier Neau, Charles Cazanave, Mathilde Puges, and the Campylobacteremia Study Group
Table 1
Characteristics of 45 patients with Campylobacter spp. vascular infections in a multicenter retrospective study on vascular infections and endocarditis caused by Campylobacter spp., France*
| Characteristic | Vascular infection | Native vascular infection | Vascular graft or endograft infection |
|---|---|---|---|
| All patients |
45 (100) |
30 (66.7) |
15 (33.3) |
| Age, y, median (interquartile range) |
69.5 (61.2–81.3) |
69.5 (61.8–81.3) |
70 (62–81) |
| Sex | |||
| M | 36 (80) | 23 (76.7) | 13 (86.7) |
| F |
9 (20) |
7 (23.3) |
2 (13.3) |
| Localization | |||
| Aortic | 30 (66.7) | 17 (56.7) | 13 (86.7) |
| Peripheral artery | 7 (15.6) | 6 (20) | 1 (6.7) |
| Venous involvement | 5 (11.1) | 4 (13.3) | 1 (6.7) |
| Lymphatic involvement | 1 (2.2) | 1 (3.3) | 0 |
| Not available |
2 (4.4) |
2 (6.7) |
0 |
| Underlying condition | |||
| Preexisting aortic aneurysm | 11 (24.4) | 9 (30) | 2 (13.3) |
| Ischemic cardiomyopathy | 10 (22.2) | 8 (26.7) | 2 (13.3) |
| Tobacco use | 12 (26.7) | 8 (26.7) | 4 (26.7) |
| Chronic liver disease | 5 (11.1) | 4 (13.3) | 1 (3.3) |
| Diabetes | 11 (24.4) | 8 (26.7) | 3 (20) |
| Chronic renal failure | 9 (20) | 5 (16.7) | 4 (26.7) |
| Hematologic malignancy | 2 (4.4) | 2 (6.7) | 0 |
| Solid neoplasm | 11 (24.4) | 6 (20) | 5 (33.3) |
| Immunodeficiency |
7 (15.6) |
6 (20) |
1 (6.7) |
| Clinical manifestations† | |||
| Fever | 32 (71.1) | 24 (80) | 8 (53.3) |
| Septic shock | 1 (2.2) | 1 (3.3) | 0 |
| Hemorrhagic shock | 4 (8.9) | 3 (10) | 1 (6.7) |
| Diarrhea | 10 (22.2) | 6 (20) | 4 (26.7) |
| Gastrointestinal bleeding | 6 (13.3) | 5 (16.7) | 1 (3.3) |
| Abdominal or lumbar pain | 23 (51.1) | 16 (53.3) | 7 (46.7) |
| Acute limb ischemia | 3 (6.7) | 3 (10) | 0 |
| Osteoarticular involvement |
4 (8.9) |
2 (6.7) |
2 (13.3) |
| Campylobacter species | |||
| C. fetus | 36 (80) | 23 (76.7) | 13 (86.7) |
| C. jejuni | 5 (11.1) | 4 (13.3) | 1 (3.3) |
| Other Campylobacter spp. | 4 (8.9) | 3 (10) | 1 (3.3) |
*Values are no. (%) except as indicated. †Signs and symptoms occurring within the past month were considered.
Page created: December 31, 2022
Page updated: October 13, 2023
Page reviewed: October 13, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.